Amneal Pharmaceuticals (AMRX)
(Real Time Quote from BATS)
$5.40 USD
+0.04 (0.75%)
Updated Apr 19, 2024 12:22 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AMRX 5.40 +0.04(0.75%)
Will AMRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMRX
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
AMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Other News for AMRX
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Amneal to Report First Quarter 2024 Results on May 3, 2024
What You Missed On Wall Street This Morning
What You Missed On Wall Street This Morning
Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues